Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2022-03-17 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2022-03-17 English
Material change report - French.pdf
Share Issue/Capital Change Classification · 95% confidence The document is titled 'DÉCLARATION DE CHANGEMENT IMPORTANT' which translates to 'Declaration of Material Change'. It details the issuance of subordinate voting shares to settle a debt owed to a consultant controlled by a company director, which is a related party transaction. The document references regulatory rules such as Regulation 61-101 concerning protection of minority shareholders in related party transactions. The content focuses on the announcement of a significant change in share issuance and related party dealings, not a full financial report or earnings release. The document length is 3293 characters, relatively short and focused on a specific corporate action. This fits the category of Major Shareholding Notification (MRQ) or possibly Share Issue/Capital Change (SHA). However, since the issuance is related to settling a debt and involves shares issued to a related party, it is more aligned with Share Issue/Capital Change (SHA) rather than just a notification of shareholding levels. Therefore, the best classification is SHA (Share Issue/Capital Change).
2022-03-17 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Material Change Report' and references 'Schedule 51-102F3', which is a form used in Canadian securities regulation for reporting material changes. The content describes the issuance of subordinate voting shares in settlement of a debt, involving a related party transaction. It includes details about the transaction, regulatory references (Regulation 61-101), and contact information for an executive officer. The document length is 3062 characters, which is relatively short and focused on a specific corporate event rather than comprehensive financial data or management discussion. It is not an annual or interim report, earnings release, or audit report. It is also not a proxy statement, dividend notice, or governance report. The document is a regulatory filing reporting a material change, which fits best under the category 'Regulatory Filings (RNS)' as a general regulatory announcement that does not fit other specific categories.
2022-03-17 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings
2022-03-17 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus or offering document for a financial instrument issued by CIBC, specifically a structured note linked to a Canadian banks index. It includes detailed terms of the instrument, hypothetical scenarios of returns, coupon payment details, issuance size, and subscription minimums. There is no indication that this is a report on financial performance, management discussion, earnings release, or regulatory filing. It is not a report publication announcement since it contains substantive content about the financial product. The document is clearly related to capital markets and financing activities, describing the terms and conditions of a capital raising instrument. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-03-17 English
News release - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Groupe Santé Devonian's shares are now trading on the OTCQB market under the symbol DVHGF. It provides background information about the company, the OTCQB market, and the benefits of this listing. There is no financial data, no detailed financial statements, no earnings results, no management discussion of financial results, no regulatory filings, no voting results, no audit information, and no other report content. The document is essentially an announcement about a capital market listing event and trading eligibility, which fits best under Capital/Financing Update (CAP). The document length is 8892 characters, which is sufficient for a full announcement rather than a brief note. Therefore, the classification is CAP with high confidence.
2022-03-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.